Floatz logo

RED BLOOD CELLS

Head Injury

ThermoFisher Scientific Brahms Biomarkers FranceCell therapyN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Head Injury cohort.

Asset / SponsorPhaseRating
Acetylsalicylic Acid
Hadassah Medical Organization
Phase 4BB
Oxygen
Jay C. Buckey Jr.
Phase 4BB
Sodium Lactate
Institut d'Anesthesiologie des Alpes Maritimes
Phase 2/3B
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Pierre-Julien CUNGI
Phase 2CCC
SUFENTANYL
Pierre-Julien CUNGI
Phase 2CCC
Rosuvastatin
Universidad Autonoma de San Luis Potosí
Phase 1/2CCC
NEPENTHE
Dalhousie University
Phase 1/2CCC
MANNITOL
Massachusetts General Hospital
Phase 1/2CCC

Same molecule, other indications

RED BLOOD CELLS is also rated in:

beta-thalassemia majorDormant
B
Indicative ·
62 / 100
View asset →
relapsing-remitting multiple sclerosisDormant
CC
Indicative ·
46 / 100
View asset →
bronchopulmonary dysplasiaDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →